Literature DB >> 14745878

Desmoplastic and neurotropic melanoma.

Lyndon D Su1, Douglas R Fullen, Lori Lowe, Timothy S Wang, Jennifer L Schwartz, Vincent M Cimmino, Vernon K Sondak, Timothy M Johnson.   

Abstract

BACKGROUND: Desmoplastic and neurotropic melanoma (DNMM) occasionally metastasizes to regional lymph nodes and extranodal sites. The value of sentinel lymph node biopsy (SLNB) has not been demonstrated clearly for patients with DNMM. The authors report on the utility of SLNB in the management of patients with DNMM.
METHODS: The authors identified 33 patients with DNMM who were seen during a 5-year period in their institution who underwent lymphatic mapping and SLNB. Clinical and histopathologic data were reviewed.
RESULTS: Thirty-three patients with DNMM underwent SLNB (mean Breslow depth, 4.0 mm; median, 2.8 mm). There were 25 male patients and 8 female patients with a median age of 61 years (range, 31-86 years). Fifty-two percent of tumors presented in the head and neck region, and 24% were associated with lentigo maligna. Four of 33 patients (12%) without clinical evidence of metastatic disease who underwent SLNB had at least 1 positive sentinel lymph node. No additional positive lymph nodes were found in subsequent therapeutic regional lymphadenectomy in any of these four patients.
CONCLUSIONS: SLNB detected subclinical metastases of DNMM to regional lymph nodes. SLNB at the time of resection can provide useful information to guide early treatment and, coupled with lymphadenectomy in positive patients, may limit tumor spread and prevent recurrence at the draining lymph node basin. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 14745878     DOI: 10.1002/cncr.11947

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

2.  Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.

Authors:  Alexander H R Varey; Chris Goumas; Angela M Hong; Graham J Mann; Gerald B Fogarty; Jonathan R Stretch; Robyn P M Saw; Andrew J Spillane; Kerwin F Shannon; Kenneth J Lee; Michael J Quinn; John F Thompson; Richard A Scolyer
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

3.  [Desmoplastic neurotropic melanoma. Diagnosis and therapeutic procedures for a rare clinical entity].

Authors:  J Hauser; H-H Homann; D Drücke; C Kuhnen; S A Esenwein; H-U Steinau
Journal:  Chirurg       Date:  2006-10       Impact factor: 0.955

4.  Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?

Authors:  Dale Han; Jonathan S Zager; Daohai Yu; Xiuhua Zhao; Brooke Walls; Suroosh S Marzban; Nikhil G Rao; Vernon K Sondak; Jane L Messina
Journal:  Ann Surg Oncol       Date:  2013-02-07       Impact factor: 5.344

5.  Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?

Authors:  Patrick Scanlon; Jaiying Tian; Judy Zhong; Ines Silva; Richard Shapiro; Anna Pavlick; Russell Berman; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2014-04-18       Impact factor: 3.466

Review 6.  Malignant melanoma with neural differentiation: an exceptional case report and brief review of the pertinent literature.

Authors:  Albert Su; Sarah M Dry; Scott W Binder; Jonathan Said; Peter Shintaku; G Peter Sarantopoulos
Journal:  Am J Dermatopathol       Date:  2014-01       Impact factor: 1.533

7.  Clinicopathologic predictors of survival in patients with desmoplastic melanoma.

Authors:  Dale Han; Gang Han; Xiuhua Zhao; Nikhil G Rao; Jane L Messina; Suroosh S Marzban; Amod A Sarnaik; C Wayne Cruse; Vernon K Sondak; Jonathan S Zager
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

8.  Desmoplastic melanoma: The role of pure and mixed subtype in sentinel lymph node biopsy and survival.

Authors:  Annelien E Laeijendecker; Mary-Ann El Sharouni; Vigfús Sigurdsson; Paul J van Diest
Journal:  Cancer Med       Date:  2019-12-05       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.